Gastroenterology
Volume 133, Issue 2 , Pages 403-411 , August 2007

Central Adiposity and Risk of Barrett’s Esophagus

  • Zoe R. Edelstein

      Affiliations

    • Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • Department of Epidemiology, University of Washington, Seattle, Washington
    • ,
  • Diana C. Farrow

      Affiliations

    • Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • Department of Epidemiology, University of Washington, Seattle, Washington
    • ,
  • Mary P. Bronner

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, Ohio
    • ,
  • Sheldon N. Rosen

      Affiliations

    • Group Health Cooperative, Seattle, Washington
    • ,
  • Thomas L. Vaughan

      Affiliations

    • Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • Department of Epidemiology, University of Washington, Seattle, Washington
    • Corresponding Author InformationAddress requests for reprints to: Thomas L Vaughan, MD, Program in Epidemiology, M4-B874, 1100 Fairview Ave N., PO Box 19024, Seattle, Washington 98109.

Received 3 January 2007 ,Accepted 3 May 2007.

References 

  1. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049–2053
  2. Jeon J, Luebeck E, Moolgavkar S. Age effects and temporal trends in adenocarcinoma of the esophagus and gastric cardia (United States). Cancer Causes Control. 2006;17:971–981
  3. Holmes RS, Vaughan T. Epidemiology and pathogenesis of esphogeal cancer. Semin Rad Oncol. 2007;17:2–9
  4. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–146
  5. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med. 1999;130:883–890
  6. Falk GW. Barrett’s esophagus. Gastroenterology. 2002;122:1569–1591
  7. Jankowski JA, Harrison RF, Perry I, Balkwill F, Tselepis C. Barrett’s metaplasia. Lancet. 2000;356:2079–2085
  8. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus. Am J Gastroenterol. 2002;97:1888–1895
  9. Sampliner RE. Epidemiology, pathophysiology, and treatment of Barrett’s esophagus: reducing mortality from esophageal adenocarcinoma. Med Clin North Am. 2005;89:293–312
  10. Samanic C, Chow WH, Gridley G, Jarvholm B, Fraumeni JF. Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control. 2006;17:901–909
  11. MacInnis RJ, English DR, Hopper JL, Giles GG. Body size and composition and the risk of gastric and oesophageal adenocarcinoma. Int J Cancer. 2006;118:2628–2631
  12. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143:199–211
  13. Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL, et al Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst. 1998;90:150–155
  14. Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med. 2006;354:2340–2348
  15. Murray L, Johnston B, Lane A, Harvey I, Donovan J, Nair P, et al. Relationship between body mass and gastro-oesophageal reflux symptoms: The Bristol Helicobacter Project. Int J Epidemiol. 2003;32:645–650
  16. Nilsson M, Johnsen R, Ye W, Hveem K, Lagergren J. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA. 2003;290:66–72
  17. Stein DJ, El-Serag HB, Kuczynski J, Kramer JR, Sampliner RE. The association of body mass index with Barrett’s oesophagus. Aliment Pharmacol Ther. 2005;22:1005–1010
  18. Smith KJ, O’Brien SM, Smithers BM, Gotley DC, Webb PM, Green AC, et al. Interactions among smoking, obesity, and symptoms of acid reflux in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 2005;14:2481–2486
  19. El-Serag HB, Kvapil P, Hacken-Bitar J, Kramer JR. Abdominal obesity and the risk of Barrett’s esophagus. Am J Gastroenterol. 2005;100:2151–2156
  20. Vaughan TL, Kristal AR, Blount PL, Levine DS, Galipeau PC, Prevo LJ, et al. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 2002;11:745–752
  21. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. The Lancet. 2005;366:1640–1649
  22. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006;47:1093–1100
  23. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334:292–295
  24. Ogunwobi O, Mutungi G, Beales ILP. Leptin stimulates proliferation and inhibits apoptosis in Barrett’s esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-e2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology. 2006;147:4505–4516
  25. Moons LM, Kusters JG, Bultman E, Kuipers EJ, van Dekken H, Tra WM, et al. Barrett’s oesophagus is characterized by a predominantly humoral inflammatory response. J Pathol. 2005;207:269–276
  26. Mueller J, Werner M, Stolte M. Barrett’s esophagus: histopathologic definitions and diagnostic criteria. World J Surg. 2004;28:148–154
  27. Sharma P, Sampliner RE. Short segment Barrett’s esophagus and intestinal metaplasia of the cardia—it’s not all symantics. !! Am J Gastroenterol. 1998;93:2303–2304
  28. Spechler SJ. Short and ultrashort Barrett’s esophagus—what does it mean?. Semin Gastrointest Dis. 1997;8:59–67
  29. Waksberg J. Sampling methods for random digit dialing. J Am Stat Assoc. 1978;73:40–46
  30. Robison L, Daigle A. Control selection using random digit dialing for cases of childhood cancer. Am J Epidemiol. 1984;120:166
  31. Sakkinen PA, Severson RK, Ross JA, Robison LL. Random-digit dialing for control selection in childhood cancer studies: the geographic proximity and demographics within matched sets. Am J Public Health. 1995;85:555–557
  32. Voigt LF, Davis S, Koepsell TD. Do cases and controls matched on the first eight digits of their telephone number share geographic proximity and socioeconomic characteristics?. Ann Epidemiol. 2006;16:299–304
  33. Lohman T, Roche AF, Martorell M. Anthropometric standardization reference manual. Chicago, IL: Human Kinetics Books; 1988;
  34. Midolo PD, Lambert JR, Russell EG, Lin SK. A practical single sample dry latex agglutination test for Helicobacter pylori antibody detection. J Clin Pathol. 1995;48:969–971
  35. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ. 1995;311:158–161
  36. World Health Organization (WHO). Obesity: preventing and managing the global epidemic. Geneva: WHO; 1997;
  37. Ilanne-Parikka P, Eriksson JG, Lindstrom J, Hamalainen H, Keinanen-Kiukaanniemi S, Laakso M, et al Prevalence of the metabolic syndrome and its components: findings from a Finnish general population sample and the Diabetes Prevention Study cohort. Diabetes Care. 2004;9:2135–2140
  38. Kronmal R. Sprurious correlation and the fallacy of the ratio standard revisted. J R Statist Soc A. 1993;156:379–392
  39. Goldblum JR, Richter JE, Vaezi M, Falk GW, Rice TW, Peek RM. Helicobacter pylori infection, not gastroesophageal reflux, is the major cause of inflammation and intestinal metaplasia of gastric cardiac mucosa. Am J Gastroenterol. 2002;97:302–311
  40. Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. J Clin Invest. 2004;113:321–333
  41. Vaughan TL, Davis S, Kristal A, Thomas DB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 1995;4:85–92
  42. Lagergren J. Controversies surrounding body mass, reflux, and risk of oesophageal adenocarcinoma. Lancet Oncol. 2006;7:347–349
  43. El-Serag HB, Tran T, Richardson P, Ergun G. Anthropometric correlates of intragastric pressure. Scand J Gastroenterol. 2006;41:887–891
  44. Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15:872–878
  45. Lagergren J, Bergstrom R, Nyren O. No relation between body mass and gastro-oesophageal reflux symptoms in a Swedish population-based study. Gut. 2000;47:26–29
  46. Rey E, Moreno-Elola-Olaso C, Artalejo FR, Locke GR, az-Rubio M. Association between weight gain and symptoms of gastroesophageal reflux in the general population. Am J Gastroenterol. 2006;101:229–233
  47. Trayhurn P, Bing C, Wood IS. Adipose tissue and adipokines—energy regulation from the human perspective. J Nutr. 2006;136:S1935–S1939
  48. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21:697–738
  49. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821–1830
  50. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–591
  51. Somasundar P, McFadden DW, Hileman SM, Vona-Davis L. Leptin is a growth factor in cancer. J Surg Res. 2004;116:337–349
  52. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer. 2006;94:1221–1225
  53. Wang Y, Lam KS, Xu JY, Lu G, Xu LY, Cooper GJ, et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem. 2005;280:18341–18347
  54. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin—the classical, resistin—the controversial, adiponectin—the promising, and more to come. Best Pract Res Clin Endocrinol Metab. 2005;19:525–546
  55. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998;83:847–850
  56. Higdon JV, Frei B. Obesity and oxidative stress: a direct link to CVD?. Arterioscler Thromb Vasc Biol. 2003;23:365–367
  57. Tsukui S, Kanda T, Nara M, Nishino M, Kondo T, Kobayashi I. Moderate-intensity regular exercise decreases serum tumor necrosis factor-α and HbA1c levels in healthy women. Int J Obes Relat Metab Disord. 2000;24:1207–1211
  58. Zahorska-Markiewicz B, Janowska J, Olszanecka-Glinianowicz M, Zurakowski A. Serum concentrations of TNF-α and soluble TNF-α receptors in obesity. Int J Obes Relat Metab Disord. 2000;24:1392–1395
  59. Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, Gomez-Reino JJ, et al. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett. 2005;579:295–301
  60. Malfertheiner P, Peitz U. The interplay between Helicobacter pylori, gastro-oesophageal reflux disease, and intestinal metaplasia. Gut. 2005;54(Suppl 1):i13–i20
  61. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett’s) esophagus (Comparison of population-based clinical and autopsy findings). Gastroenterology. 1990;99:918–922

 Supported by US National Institutes of Health (grant number R01 CA72866) and P01 CA091955.

 Conflicts of interest: None.

PII: S0016-5085(07)01008-6

doi: 10.1053/j.gastro.2007.05.026

Gastroenterology
Volume 133, Issue 2 , Pages 403-411 , August 2007

Article Tools